Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
muscular dystrophy
Biotech
Avidity therapy shows possible benefit in muscular dystrophy
Avidity's del-brax demonstrated a safe profile and was tied to functional improvement among people with FSHD in a phase 1/2 trial.
Gabrielle Masson
Jun 12, 2024 7:00am
Sanofi pays Fulcrum $80M for rights to phase 3 rare disease drug
May 13, 2024 7:09am
PepGen gains a little pep in its step as FDA clears trial hold
Oct 12, 2023 7:00am
Sanofi wagers $400M in biobucks to go after muscular dystrophy
Oct 4, 2022 8:00am
Cancer drug delays DMD progression in mice
Jul 1, 2022 3:10pm
BridgeBio plots path to market for muscular dystrophy drug
Mar 14, 2022 7:30am
